Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acylglucosamine 2-epimerase (RENBP)
- Target
- RENBP
- Molecular classification
- Enzyme, Isomerase (specifically a carbohydrate epimerase), Enzyme inhibitor (of renin)
01
Overview
N-acylglucosamine 2-epimerase (RENBP) is a human enzyme encoded by the RENBP gene. It inhibits renin by dimerizing with the enzyme, contributing to regulation of blood pressure via the renin-angiotensin system. RENBP’s main enzymatic role is the interconversion of N-acetylglucosamine and N-acetylmannosamine, which positions it centrally in aminosugar metabolism and the sialic acid pathway. Genetic variants in RENBP are associated with inherited conditions (colorblindness, sialuria), and its activity links to both protein glycosylation and cardiovascular regulation. RENBP also contains a leucine zipper domain necessary for protein-protein interactions, including dimerization with renin
- Other names
- RENBPAGERnBPRNBPRBPGlcNAc 2-epimeraseN-acetyl-D-glucosamine 2-epimeraseRenin-binding proteinN-acylglucosamine 2-epimerase
02
Mechanism of action
Enzyme inhibition: RENBP binds and inactivates renin, forming a renin-RENBP complex. Carbohydrate epimerization: catalyzes the conversion between N-acetylglucosamine and N-acetylmannosamine. Catabolic regulation: diverts metabolic flux away from sialic acid biosynthesis.
03
Biological functions
Enzyme inhibition (inhibits renin activity)Carbohydrate metabolism (interconversion of N-acetylglucosamine and N-acetylmannosamine)N-glycan biosynthesis (related pathway)Sialic acid metabolism (catabolic role)
04
Disease associations
Colorblindness, partial, protan series (gene association)Sialuria (gene association)Cardiovascular disease (through the blood pressure-regulating renin-angiotensin system)Other (potential metabolic and genetic disorders due to its enzymatic function)
05
Safety considerations
No major safety concerns reported in the literature regarding RENBP as a drug target; limited data on adverse effects.Potential metabolic consequences if the enzymatic activity is broadly inhibited, since sialic acid and carbohydrate metabolism are fundamental cellular processes
06
Interacting drugs
Small molecule inhibitors of GlcNAc 2-epimerase have been developed for metabolic studies, but there are no widely used clinical drugs directly targeting RENBP
1 more in the full profile.
07
Biomarkers
RENBP genetic variants may affect prorenin levels in plasma, indicating potential biomarker utilityPolymorphisms (intronic T/C) in RENBP could serve as genetic markers in relevant diseases
Beyond the preview
Go deeper on N-acylglucosamine 2-epimerase (RENBP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-acylglucosamine 2-epimerase (RENBP).